Dr Will Herrington
Contact information
| will.herrington@ndph.ox.ac.uk | |
| Tel | +44 (0)1865 743926 |
| Website | http://Twitter feed: @willkidney |
Will Herrington
MD, MRCP
Senior Clinical Research Fellow, Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit
Will Herrington studied medicine at University of Cambridge and University College London (1997-2003) and has practised in nephrology since 2006. He was appointed an Honorary Consultant Nephrologist at Oxford Kidney Unit in 2014. He joined the Renal Studies Group at CTSU in 2010 as a Clinical Research Fellow and worked on SHARP and 3C, two landmark trials in nephrology. He was awarded an MD from the University of Cambridge in 2013 for his thesis entitled ‘The effects of lowering LDL cholesterol on stroke in chronic kidney disease’ and retains a key interest in the safety and efficacy of lowering LDL cholesterol on both renal and vascular outcomes in people with chronic kidney disease.
His current research also focuses on understanding the key determinants of developing kidney disease and cardiovascular disease and the use of routine healthcare data and mobile technology for large-scale renal epidemiology and streamlined randomized trials.
He works with the SHARP, the Mexico City Prospective Study, the Cholesterol Treatment Trialists' Collaboration, UK Biobank, Clincal Practice Research Datalink data, China-Kadooire Biobank, and the Prospective Studies Collaboration, and aims to understand how adiposity and diabetes (and associated risk factors including lipids and blood pressure) impact on renal and cardiovascular health in a wide range of populations.
He is module co-lead for the Record Linkage and Bioinformatics module in the department’s MSc in Global Health Science, is a subject editor for the Clinical Kidney Journal, an adviser to the Kidney Health Initiative and Clinical Trials Transformation Initiative and Scientific Co-ordinator for the KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology.
Key publications
5-
Diabetes and Cause-Specific Mortality in Mexico City.
Alegre-Díaz J. et al, (2016), N Engl J Med, 375, 1961 - 1971
-
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Baigent C. et al, (2011), Lancet, 377, 2181 - 2192
-
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.
Cholesterol Treatment Trialists' (CTT) Collaboration None. et al, (2016), Lancet Diabetes Endocrinol, 4, 829 - 839
-
Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.
Herrington W. et al, (2017), Hypertension, 69, 314 - 322
-
Association Between Diabetes and Cause-Specific Mortality in Rural and Urban Areas of China.
Bragg F. et al, (2017), JAMA, 317, 280 - 289
Recent Publications
5-
A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease.
Schlackow I. et al, (2017), Heart
-
Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.
Baigent C. et al, (2017), Kidney Int, 92, 297 - 305
-
Tightening our understanding of intensive glycaemic control.
Herrington WG. and Preiss D., (2017), Lancet Diabetes Endocrinol, 5, 405 - 407
-
The Role of Emerging Risk Factors in Cardiovascular Outcomes.
Lacey B. et al, (2017), Curr Atheroscler Rep, 19
-
Biliary Tract and Liver Complications in Polycystic Kidney Disease.
Judge PK. et al, (2017), J Am Soc Nephrol